While certain molecular features can identify tumors at high risk of treatment failure, including amplification and/or overexpression of MYC in Group 3 medulloblastoma (6), limited therapeutic options exist for patients following relapse and there are minimal genetic changes in Group 3 tumors that can be therapeutically targeted at this disease stage (7). Here, MYC is linked to medulloblastoma.